Last patient recruited into phase I trial on multiple sclerosis in STRATEGMED TREGS programme. Full results of the study will be available in second quarter of 2019.
More:
2018-01-01
January 2018
See other news
2023-06-15
PolTREG is expanding its cGMP capabilities, which are currently out-sourced, with the announcement of the completion of the first stage investment in and construction of its own state-of-the art cell and gene therapy manufacturing facility
2023-05-25
Prof. Piotr Trzonkowski, CEO of PolTREG has been awarded the Wprost Health Visioner 2023 Award
